Dr. Hossein Ardehali MD, PhD
Associate Professor, Northwestern University, Feinberg School of Medicine
Member of the Healthcare Council
Council Member Biography
Hossein Ardehali, MD, PhD, is an Associate Professor of Medicine at Northwestern University in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research is in the areas of reperfusion injury and cardio protection against ischemic injury. He is also involved in several projects involving prevention of coronary artery disease, role of inflammation in atherosclerosis, antiplatelets in heart disease, and statins in inflammation and coronary disease. Dr. Ardehali has received numerous awards, including the American Heart Association (AHA) BCVS Young Investigator Award, the Jeremiah Stamler Distinguished Young Investigator Award, and GSK International Award for Young Investigators and the Schweppe Foundation Award. He is a fellow of the AHA and American College of Cardiology. Dr. Ardehali serves on numerous AHA committees, including the AHA BCVS leadership committee and is the AHA BCVS communication/Membership committee. (This is me - Update Profile)
Employment History
- 2010 - Unspecified
- Associate Professor, Northwestern University, Feinberg School of Medicine
- 2005 - 2010
- Assistant Professor, Northwestern University, Feinberg School of Medicine
- 2004 - 2005
- Instructor, JOHNS HOPKINS UNIVERSITY
GLG NewsSM Analyses by Hossein Ardehali
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
New studies suggest DES may improve outcome in the setting of AMI
September 19, 2006
NEJM Articles on DES in MI | content.nejm.org
The studies reported in the recent issues of NEJM are significant in that they provide evidence that DES in the setting of AMI with ST elevation may improve outcome. Taxel-eluting stents showed nonsignificant improvement in adverse cardiac events, but sirolimus-eluting stents showed a significant reduction in target vessel revascularization
-
Generic clopidogrel should not alter its use
August 18, 2006
Mixed thoughts on how generic clopidogrel might impact patients, providers | www.theheart.org
There are clear indications to use clopidogrel
Clopidogrel should not be used in every patient with coronary artery disease
GLG Study Groups with Hossein Ardehali(?)
| Study Group Name | No. Members |
|---|---|
| Heart Failure Specialists (US) | 1083 |
| Physicians who Treat Hypertension (US) | 949 |
| Non-Electrophysiologist Cardiologists (US) | 849 |
| Physicians who Treat Peripheral Vascular Disease | 340 |
| Physicians who Treat Arrhythmia (US) | 322 |
GLG Live Meetings with Hossein Ardehali(?)
Hossein Ardehali has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.